Firebrick Pharma Ltd (FRE) - Total Assets
Based on the latest financial reports, Firebrick Pharma Ltd (FRE) holds total assets worth AU$1.83 Million AUD (≈ $1.29 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See FRE total equity for net asset value and shareholders' equity analysis.
Firebrick Pharma Ltd - Total Assets Trend (2019–2025)
This chart illustrates how Firebrick Pharma Ltd's total assets have evolved over time, based on quarterly financial data.
Firebrick Pharma Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Firebrick Pharma Ltd's total assets of AU$1.83 Million consist of 81.2% current assets and 18.8% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 53.8% |
| Accounts Receivable | AU$257.81K | 14.1% |
| Inventory | AU$193.98K | 10.6% |
| Property, Plant & Equipment | AU$94.50K | 5.2% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Firebrick Pharma Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see FRE market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Firebrick Pharma Ltd's current assets represent 81.2% of total assets in 2025, a decrease from 99.9% in 2019.
- Cash Position: Cash and equivalents constituted 53.8% of total assets in 2025, up from 49.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 14.1% of total assets.
Firebrick Pharma Ltd Competitors by Total Assets
Key competitors of Firebrick Pharma Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
SW:NOVN
|
Switzerland | CHF115.49 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $133.96 Billion |
|
Roche Holding AG
SW:ROG
|
Switzerland | CHF100.70 Billion |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
|
China | CN¥17.48 Billion |
|
AstraZeneca PLC
LSE:AZN
|
UK | GBX114.07 Billion |
|
Shandong Keyuan Pharmaceutical Co. Ltd. A
SHE:301281
|
China | CN¥1.60 Billion |
|
Korean Drug Co. Ltd
KQ:014570
|
Korea | ₩95.05 Billion |
|
SANOFI CONS HEALTHC IND L
NSE:SANOFICONR
|
India | Rs5.47 Billion |
Firebrick Pharma Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.47 | 7.19 | 7.77 |
| Quick Ratio | 4.75 | 6.36 | 7.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$1.21 Million | AU$1.80 Million | AU$1.45 Million |
Firebrick Pharma Ltd - Advanced Valuation Insights
This section examines the relationship between Firebrick Pharma Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.18 |
| Latest Market Cap to Assets Ratio | 5.18 |
| Asset Growth Rate (YoY) | -24.0% |
| Total Assets | AU$1.83 Million |
| Market Capitalization | $9.47 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Firebrick Pharma Ltd's assets at a significant premium (5.18x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Firebrick Pharma Ltd's assets decreased by 24.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Firebrick Pharma Ltd (2019–2025)
The table below shows the annual total assets of Firebrick Pharma Ltd from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$1.83 Million ≈ $1.29 Million |
-24.05% |
| 2024-06-30 | AU$2.41 Million ≈ $1.70 Million |
-19.32% |
| 2023-06-30 | AU$2.98 Million ≈ $2.11 Million |
-65.83% |
| 2022-06-30 | AU$8.73 Million ≈ $6.18 Million |
-25.82% |
| 2021-06-30 | AU$11.77 Million ≈ $8.33 Million |
+1697.18% |
| 2020-06-30 | AU$654.81K ≈ $463.32K |
-44.34% |
| 2019-06-30 | AU$1.18 Million ≈ $832.41K |
-- |
About Firebrick Pharma Ltd
Firebrick Pharma Limited engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.